We are live on ! Find out more
BIOA

BioAge Labs
BIOA

65 hedge funds and large institutions have $114M invested in BioAge Labs in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 29

12% more funds holding

Funds holding: 58 → 65 (+7)

0% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 11

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

74% less capital invested

Capital invested by funds: $431M → $114M (-$317M)

1,149.26% less ownership

Funds ownership: 1,204.05% → 54.79% (-1,149%)

Holders
65
Holders Change
+7
Holders Change %
+12.07%
% of All Funds
0.86%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.07%
New
36
Increased
11
Reduced
11
Closed
29
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$22.7M
2
CAM
Cormorant Asset Management
Massachusetts
+$17.2M
3
BlackRock
BlackRock
New York
+$12.3M
4
Morgan Stanley
Morgan Stanley
New York
+$7.6M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$5.46M

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$20.7M
2
RCM
RA Capital Management
Massachusetts
-$15.5M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$9.36M
4
O
OrbiMed
New York
-$8.65M
5
Brown Advisory
Brown Advisory
Maryland
-$6.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AH Capital Management
California
$18.7M +$3.78M +219,195 +7%
CAM
2
Cormorant Asset Management
Massachusetts
$15.2M +$17.2M +1,000,000 +61%
SI
3
Sofinnova Investments
California
$13.3M – – –
SCM
4
Suvretta Capital Management
New York
$8.41M -$45.9K -2,664 -0.2%
TCM
5
Tang Capital Management
California
$7.63M +$22.7M +1,318,361 New
RCM
6
RA Capital Management
Massachusetts
$7.59M -$15.5M -900,000 -41%
O
7
OrbiMed
New York
$5.34M -$8.65M -501,511 -35%
SCV
8
Sands Capital Ventures
Virginia
$4.55M -$5.17M -300,000 -28%
RI
9
RTW Investments
New York
$4.55M – – –
BlackRock
10
BlackRock
New York
$4.12M +$12.3M +712,394 New
PBPIA
11
Pivotal bioVenture Partners Investment Advisor
California
$3.78M +$2.17M +125,727 +24%
Morgan Stanley
12
Morgan Stanley
New York
$2.56M +$7.6M +440,644 +19,084%
SL
13
Siren LLC
Connecticut
$2.25M +$1.52M +88,000 +29%
RM
14
Redpoint Management
California
$2.22M – – –
Vanguard Group
15
Vanguard Group
Pennsylvania
$2.07M +$5.46M +316,798 +792%
CFM
16
Comprehensive Financial Management
California
$1.57M – – –
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.49M +$4.43M +256,995 New
Goldman Sachs
18
Goldman Sachs
New York
$1.13M +$1.51M +87,351 +80%
Fidelity International
19
Fidelity International
Bermuda
$847K -$927K -53,785 -27%
ACM
20
ADAR1 Capital Management
Texas
$712K +$2.12M +123,037 New
HHMI
21
Howard Hughes Medical Institute
Maryland
$659K – – –
UBS Group
22
UBS Group
Switzerland
$602K +$1.79M +103,891 New
WP
23
Woodline Partners
California
$512K -$631K -36,582 -29%
Northern Trust
24
Northern Trust
Illinois
$505K +$1.5M +87,243 New
Charles Schwab
25
Charles Schwab
California
$491K +$1.46M +84,867 New
1
2 3 4

BIOA Hedge Fund Activity: Q4 2024 in Review

65 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in BioAge Labs (BIOA) for Q4 2024, worth a combined $114M — down 74% from $431M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new BIOA positions and 29 closed out — a net gain of 7 holders — while 11 added to existing stakes and 11 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $22.7M. The largest seller was AllianceBernstein, exiting entirely with an estimated $20.7M sold.

  • 65 institutional investors held BioAge Labs (BIOA) as of Q4 2024, up from 58 in Q3 2024.
  • Funds reported $114M of BioAge Labs stock for Q4 2024, down 74% quarter-over-quarter.
  • 36 funds opened new BioAge Labs positions in Q4 2024 and 29 closed out, a net change of +7 holders.
  • The largest BioAge Labs buyer in Q4 2024 was Tang Capital Management, an estimated $22.7M added.
  • The largest BioAge Labs seller in Q4 2024 was AllianceBernstein, an estimated $20.7M sold.

Based on aggregated 13F filings for Q4 2024.